The company recently guided for FY24 revenue of $428M-$432M, consensus $430.97M. Analysts expect the company to report FY25 revenue of $543.99. Guidance taken from Investor Day. Shares of TransMedics (TMDX) are down 3.4% in afternoon trading.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX: